

Effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN<sup>®</sup>) on the Vaginal Health Index Score (VHIS) and Female Sexual Function Index (FSFI) in patients with vaginal de-epithelialization: a prospective, single-center cohort analysis

Antonio Simone Laganà<sup>1</sup>, Benito Chiofalo<sup>1</sup>, Roberta Granese<sup>1</sup>, Vittorio Palmara<sup>1</sup>, Onofrio Triolo<sup>1</sup>

<sup>1</sup> Gynecology and Obstetrics Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy

### ABSTRACT

**Objective:** to evaluate the effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN<sup>®</sup>) on the Vaginal Health Index Score (VHIS) and Female Sexual Function Index (FSFI) in patients with vaginal de-epithelialization.

**Materials and methods**: we enrolled 45 postmenopausal women with vaginal de-epithelialization, who underwent VHIS evaluation and completed an FSFI test. We recorded their age, age at onset of menopause, parity and Body Mass Index. After this baseline evaluation, patients underwent 30 days of vaginal treatment with one capsule per day of TIAGIN<sup>®</sup>. After treatment, all patients were evaluated again using the same methods as the pre-treatment phase.

**Results**: after treatment there was significant improvement in all VHIS parameters (elasticity, fluid secretion type and consistency, pH, epithelialization of vaginal mucosa, and moisture) and in the total score (p=0.006). Similarly, after treatment there was also a significant improvement in 4 FSFI areas (lubrication, orgasm, satisfaction, and pain) and in the total score (p=0.005). None of the patients reported any local or systemic side effects during treatment.

**Conclusions**: we observed a significant improvement in both the VHIS and FSFI, which can be considered direct and indirect signs of increased vaginal epithelialization following vaginal treatment with TIAGIN<sup>®</sup>.

**Keywords**: Aloe Vera, silver ions, Vaginal Health Index Score, Female Sexual Function Index (FSFI), vaginal de-epithelialization.

Corresponding to: antlagana@unime.it Copyright 2017, Partner-Graf srl, Prato DOI: 10.14660/2385-0868-61

#### **SOMMARIO**

**Obiettivo**: valutare gli effetti di microcristalli di biossido di titanio con ioni d'argento covalentemente legati ed estratti di Aloe Barbadensis (TIAGIN<sup>®</sup>) sul Vaginal Health Index Score (VHIS) e Female Sexual Function Index (FSFI) in pazienti affette da disepitelizzazione vaginale.

**Materiali e metodi**: abbiamo arruolato 45 donne in post-menopausa affette da disepitelizzazione vaginale, valutate mediante VHIS e FSFI. Abbiamo registrato età, età di insorgenza della menopausa, parità e Body Mass Index. Dopo la valutazione iniziale, le pazienti sono state trattate con una capsula vaginale al giorno di TIAGIN<sup>®</sup>, per 30 giorni. Dopo il trattamento, tutte le pazienti sono state rivalutate usando la stessa metodologia applicata durante la valutazione iniziale pre-trattamento.

**Risultati**: dopo il trattamento abbiamo osservato un miglioramento significativo di tutti i parametri del VHIS (elasticità, tipo e consistenza della secrezione, pH, epitelizzazione e umidificazione della mucosa vaginale) e dello score totale (p=0.006). Parallelamente, abbiamo osservato anche un miglioramento di 4 domini del FSFI (lubrificazione, orgasmo, soddisfazione, dolore) e dello score totale (p=0.005). Nessuna delle pazienti ha riportato effetti indesiderati locali o sistemici durante il trattamento.

**Conclusioni**: i nostri dati dimostrano significativi miglioramenti sia del VHIS che del FSFI, che possono essere considerati segni indiretti dell'aumentata epitelizzazione vaginale dopo trattamento con TIAGIN<sup>®</sup>. It. J. Gynaecol. Obstet. 2017, 29: N. 1 - Supplement

# INTRODUCTION

There is mounting evidence to suggest that sexual health plays a pivotal role throughout women's lives, from puberty to the postmenopausal period<sup>(1,2)</sup>. According to the World Health Organization, sexual health requires a positive approach to human sexuality and an understanding of the complex factors that shape human sexual behavior<sup>(3)</sup>. Despite the need for more epidemiological research into female sexual dysfunction (FSD), it is widely acknowledged that it increases as women age and affects about 40-45% of adult women<sup>(4)</sup>. To this regard, common risk factor categories associated with FSD include individual general state of health, diabetes mellitus, cardiovascular disease, other genitourinary diseases, psychiatric/psychological disorders, other chronic diseases, and sociodemographic conditions<sup>(5-8)</sup>. Nevertheless, the multidimensional nature of human sexuality may also play a detrimental part in objectifying the real contributing factors to possible dysfunctions<sup>(9,10)</sup>.

On the basis of these elements, several approaches and methods have already been proposed in order to recognize and measure sexual health, FSD rate, and severity. As has been widely reviewed by Rosen<sup>(11)</sup>, on one hand objective measures, such as vaginal photoplethysmography or Duplex ultrasound, have been used in some studies but lack standardization and are unsuitable for use in large-scale clinical trials, while on the other hand, self-reported event logs or questionnaires are best suited for research or clinical assessment of female sexual function. Among these questionnaires, one of most used and validated is the Female Sexual Function Index (FSFI)<sup>(12)</sup>, which consists of 19 items designed to asses 6 important areas of female sexuality: desire, arousal, lubrication, orgasm, satisfaction, and pain. In addition to these important determining factors, numerous studies have reported that adequate vaginal epithelialization is strictly related to satisfactory quantity and quality of sexual activity<sup>(13)</sup>, even after autologous in vitro cultured vaginal tissue transplantation in patients with Meyer-von-Rokitansky-Küster-Hauser syndrome<sup>(14,15)</sup>. Like the FSFI, the need for an objective and measurable evaluation of vaginal mucosa led to the development of the Vaginal Health Index Score (VHIS)<sup>(16)</sup>, which analyzes overall elasticity, fluid secretion type and consistency, pH, epithelialization of vaginal mucosa, and moisture.

Several pharmacological treatments have already been developed to improve vaginal epithelialization and, consequently, sexual health in the female population<sup>(17,18)</sup>. Nevertheless, current data is still not sufficient to draw any firm conclusions regarding the gold standard treatment. Recent evidence reported that Aloe Vera extracts have significant antioxidant<sup>(19)</sup>, antibacterial<sup>(20)</sup>, anti-inflammatory, and woundhealing properties<sup>(21)</sup>. Furthermore, similar beneficial properties were reported for silver ions<sup>(22-24)</sup>.

Considering these elements and the lack of robust available data in literature, the aim of the current study is to evaluate the effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN<sup>®</sup>) on the VHIS and FSFI in patients with vaginal de-epithelialization.

## MATERIALS AND METHODS

We performed a prospective, single-center cohort analysis between March and May 2016 at the Gynecology and Obstetrics Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina (Messina, Italy). We enrolled post-menopausal women with vaginal de-epithelialization, excluding patients with significant comorbidities (chronic cardiovascular, immune, endocrine, and metabolic disorders, and cancers) and patients who had used any other kind of pharmacological treatment (including the substances tested in this study) during the previous 3 months.

The study design complies with the Declaration of Helsinki, conforms to the Committee on Publication Ethics (COPE) guidelines (http://publicationethics.org), and was approved by the Institutional Review Board (IRB) of the hospital where it was performed. Each patient who participated in this study was fully informed of the procedures involved and signed a consent form for data collection for research purposes.

All the design, analysis, data interpretation, drafting, and revision processes complied with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies<sup>(25)</sup>, available through the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) network (http://www.equator-network.org).

For all the enrolled patients, we recorded age, age at onset of menopause, parity, and Body Mass Index (BMI). All the patients underwent VHIS evaluation (as described by Bachmann et al.) <sup>(16)</sup>, always performed by the same gynecologist in order to avoid inter-observer variability, and completed the FSFI test.

After this baseline evaluation, all the enrolled patients underwent 30 days of vaginal treatment with one capsule per day of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN®). Any patient taking less than 80% of the allocated dose of study drug was regarded as noncompliant and excluded from the study. The study drug was supplied free of charge and none of the enrolled patients were paid to join or continue the study.

After treatment, all the patients were evaluated again using the same methods as the pre-treatment phase (VHIS evaluation by the same gynecologist who performed it during the pre-treatment phase and self-reported FSFI). All the side effects were recorded and an independent data safety and monitoring committee evaluated the study results.

Statistical analyses were performed by using the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) software package. The assumption of normal distribution for continuous variables was tested with the Kolmogorov–Smirnov test for goodness of fit. Continuous variables were compared between pre- and post-treatment phases using the Student t-test. A p-value of <0.05 was considered statistically significant.

### RESULTS

We enrolled 45 patients who met the inclusion/ exclusion criteria and signed an informed consent form. Age, age at onset of menopause, parity, and BMI are reported in **Table 1**. All the patients declared that they took at least 90% of the allocated dose of study drug (good compliance).

#### Table 1.

Characteristics of enrolled patients

	Mean ± Standard Deviation
Age	56.9 ± 10.0
Age of menopause onset	$48.8 \pm 2.9$
Parity	$2.3 \pm 0.8$
Body Mass Index	23.8 ± 3.2

Pre- and post-treatment VHIS results are reported in **Table 2**, whereas results for FSFI are reported in **Table 3**. In particular, after treatment there was a significant improvement in all VHIS parameters (elasticity, fluid secretion type and consistency, pH, epithelialization of vaginal mucosa, and moisture) and in the total score (p=0.006). Similarly, after the treatment there was also a significant improvement in 4 FSFI areas (lubrication, orgasm, satisfaction, and pain) and in the total score (p=0.005), whereas the improvement for the remaining 2 areas (desire, arousal) was not significant (p=0.126 and p=0.082, respectively). None of the patients reported any local or systemic side effects during treatment.

Table 2.

Comparison of Vaginal Health Index Score between pre-treatment and post-treatment phases.

Vaginal Health Index parameters	<b>Pre-treatment</b> (Mean ± Standard Deviation)	Post-treatment (Mean ± Standard Deviation)	р
Elasticity	$2.4 \pm 0.8$	$2.7 \pm 0.5$	0.036
Fluid Secretion type and consistency	$2.0 \pm 0.8$	$2.3 \pm 0.5$	0.036
pН	$2.3 \pm 0.8$	$2.6 \pm 0.6$	0.047
Epithelial mucosa	$2.3 \pm 0.8$	$2.6 \pm 0.5$	0.036
Moisture	$2.6 \pm 0.7$	$2.9 \pm 0.7$	0.045
Vaginal Health Index Score	$11.6 \pm 3.0$	13.1 ± 1.9	0.006

Table 3.

Comparison of Female Sexual Function Index between pre-treatment and post-treatment phases.

Female Sexual Function Index parameters	Pre-treatment (Mean ± Standard Deviation)	<b>Post-treatment</b> (Mean ± Standard Deviation)	р
Desire	3.7 ± 1.1	$4.0 \pm 0.7$	0.126
Arousal	$3.2 \pm 0.7$	$3.4 \pm 0.3$	0.082
Lubrication	2.8 ± 0.7	3.1 ± 0.4	0.014
Orgasm	3.3 ± 1.0	3.7 ± 0.7	0.031
Satisfaction	$3.8 \pm 0.8$	$4.1 \pm 0.4$	0.027
Pain	2.8 ± 1.3	3.3 ± 0.7	0.024
Female Sexual Function Index score	19.5 ± 3.9	$21.4 \pm 2.0$	0.005

# DISCUSSION

Sexual wellbeing has attracted growing attention and increased in importance over recent decades, both for men and women. Since the first pioneering studies in 1960, researchers have taken many steps forward in understanding the complex mechanisms behind female sexuality<sup>(26,27)</sup>. In addition to the important psychological aspects that may affect it<sup>(28)</sup>, there is mounting evidence to suggest that the vaginal microenvironment plays a pivotal role in modulating moisture and pain perception during intercourse<sup>(29-31)</sup>. Although vaginal cytokine levels are not linked to postmenopausal vulvovaginal symptoms<sup>(32)</sup>, it is possible that hormonal modifications (especially in post-menopause) may alter the vaginal microbiome and leukocyte polarization<sup>(33,34)</sup>, two key elements responsible for pain modulation<sup>(35)</sup>.

Several treatments have already been developed to improve vaginal epithelialization and ameliorate related symptoms and signs<sup>(36-38)</sup>, although the available studies differ significantly in terms of the methods used and thus in the results obtained, making it difficult to identify the best approach. Very few studies have investigated the effects of Aloe and silver ions on the vaginal microenvironment, although this data could be misinterpreted since in most studies the researchers mixed these two compounds with others(39), or data analysis was based on animal models<sup>(40)</sup>. To the best of our knowledge, this is the first report on the effects of silver ions and extracts of Aloe Vera in patients with vaginal de-epithelialization.

Our analysis demonstrated a significant improvement in both the VHIS (p=0.006) and FSFI (p=0.005), which can be considered direct (VHIS) and indirect (FSFI) signs of increased vaginal epithelialization. On the one hand, all the most

# important vaginal health parameters increased, whereas on the other hand the latter indirectly ameliorated female sexual functions. Indeed, all the FSFI parameters increased significantly, with the exception of desire and arousal, which may be more dependent on the patient's psychological state<sup>(41)</sup>.

Despite our significant results, the study was affected by several limitations. Firstly, we did not use a control group, although we opted for this study design since it would have been unethical not to provide any therapy to patients with vaginal de-epithelialization or to administer them a placebo. Moreover, our study was not blind, so patients and researchers were all aware of the purpose of the investigation and the drugs being used. What is more, our analysis was limited to the post-menopausal period and the study population was quite small.

Considering these latter elements, we would like to take this opportunity to encourage future studies with greater statistical power, which may confirm our results within larger cohorts. Furthermore, future research should explore whether treatment with silver ions and Aloe Vera extract could increase vaginal fluid levels of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which are the most important mediators responsible for re-epithelialization.

# DECLARATION OF INTEREST

This study did not receive any grants or funding. The authors have no proprietary, financial, professional, or other personal interest of any nature in any product, service, or company.

### REFERENCES

1) Slater C, Robinson AJ. **Sexual health in adolescents**. Clin Dermatol 2014;32:189–95.

2) Schwenkhagen A. **Hormonal changes in menopause** and implications on sexual health. J Sex Med 2007;4 Suppl 3:220–6.

3) World Health Organization. **Defining Sexual Health**. World Heal Organ 2006:0–30.

4) Derogatis LR, Burnett AL. **The epidemiology of sexual dysfunctions**. J Sex Med 2008;5:289–300.

5) Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, et al. **Epidemiology/risk factors of sexual dysfunction**. J Sex Med 2004;1:35–9.

6) Laganà AS, Burgio MA, Ciancimino L, Sicilia A, Pizzo A, Magno C, et al. Evaluation of recovery and quality of sexual activity in women during postpartum in relation to the different mode of delivery: a retrospective analysis. Minerva Ginecol 2015;67:315–20.

7) Laganà AS, Burgio MA, Retto G, Pizzo A, Granese R, Sturlese E, et al. **Management of the second phase of labour: perineum protection techniques**. Minerva Ginecol 2015;67:289–96.

8) Laganà AS, Terzic M, Dotlic J, Sturlese E, Palmara V, Retto G, et al. The role of episiotomy in prevention of genital lacerations during vaginal deliveries - results from two european centers. Ginekol Pol 2015;86:168-75. 9) Barbara G, Pifarotti P, Facchin F, Vercellini P. The "Kaleidoscopic" Nature of Female Sexuality: The Importance of a Comprehensive Approach to Sexual Functioning. J Sex Med 2016;13:1143–4.

10) Laganà AS, Platania A, Butticè S, Vitale SG. Comment on "Impact of Mode of Delivery on Female Postpartum Sexual Functioning: Spontaneous Vaginal Delivery and Operative Vaginal Delivery vs Cesarean Section". J Sex Med 2016;13:1142–3.

11) Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril 2002;77 Suppl 4:S89–93.

12) Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. **The Female Sexual Function Index** (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.

13) Engeland CG, Sabzehei B, Marucha PT. **Sex hormones and mucosal wound healing**. Brain Behav Immun 2009;23:629–35.

14) Nodale C, Vescarelli E, D'Amici S, Maffucci D, Ceccarelli S, Monti M, et al. **Characterization of human vaginal mucosa cells for Autologous in vitro cultured vaginal tissue transplantation in patients with MRKH syndrome**. Biomed Res Int 2014;2014:201518.

15) Panici PB, Bellati F, Boni T, Francescangeli F, Frati L, Marchese C. **Vaginoplasty using autologous in vitro cultured vaginal tissue in a patient with Mayer-von-Rokitansky-Kuster-Hauser syndrome**. Hum Reprod 2007;22:2025–8.

16) Bachmann GA, Notelovitz M, Kelly SJ, Owens A, Thompson C. Long-term nonhormonal treatment of vaginal dryness. Clin Pr Sex 1992;8:8.

17) Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60.

18) Lima SM, Yamada SS, Reis BF, Postigo S, Galvão da Silva MA, Aoki T. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas 2013;74:252–8.
19) Hu Y, Xu J, Hu Q. Evaluation of Antioxidant Potential of Aloe vera (Aloe barbadensis Miller) Extracts. J Agric Food Chem 2003;51:7788–91.

20) Ferro VA, Bradbury F, Cameron P, Shakir E, Rahman SR, Stimson WH. In vitro susceptibilities of Shigella flexneri and Streptococcus pyogenes to inner gel of Aloe barbadensis Miller. Antimicrob Agents Chemother 2003;47:1137–9.

21) Farzadinia P, Jofreh N, Khatamsaz S, Movahed A, Akbarzadeh S, Mohammadi M, et al. **Anti-inflammatory and Wound Healing Activities of Aloe vera, Honey and Milk Ointment on Second-Degree Burns in Rats**. Int J Low Extrem Wounds 2016;15:241–7.

22) Tian J, Wong KKY, Ho CM, Lok CN, Yu WY, Che CM, et al. **Topical delivery of silver nanoparticles promotes wound healing**. ChemMedChem 2007;2:129–36.

23) Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. **Effect** of silver on burn wound infection control and healing: **Review of the literature**. Burns 2007;33:139–48.

24) Babu R, Zhang J, Beckman EJ, Virji M, Pasculle WA, Wells A. Antimicrobial activities of silver used as a polymerization catalyst for a wound-healing matrix. Biomaterials 2006;27:4304–14.

25) von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. **The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies**. J Clin Epidemiol 2008;61:344–9.

26) Baumeister RF, Twenge JM. Cultural suppression of female sexuality. Rev Gen Psychol 2002;6:166–203.
27) Padgug RA. Sexual Matters: On Conceptualizing Sexuality n History. Radic Hist Rev 1979:3–23.
28) Jayne C, Gago BA. Diagnosis and treatment of female sexual arousal disorder. Clin Obstet Gynecol 2009;52:675–81.

29) Castelo-Branco C, Biglia N, Nappi RE, Schwenkhagen A, Palacios S. **Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection**. Maturitas 2015;81:462–9.

30) Nappi RE, Palacios S. **Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause**. Climacteric 2014;17:3–9.

31) Levine KB, Williams RE, Hartmann KE. **Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women**. Menopause 2008;15:661–6.

32) Stute P, Kollmann Z, Bersinger N, von Wolff M, Thurman AR, Archer DF. **Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation**. Menopause 2014;21:840–5.

33) Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 2011;6:e26602.
34) Archer DF. Vaginal atrophy and disease susceptibility: the role of leukocytes. Menopause 2015;22:804–5.

35) Thomson JC. Chronic inflammation of the peritoneum and vagina: review of its significance, immunologic pathogenesis, investigation and rationale for treatment. J Reprod Med 2005;50:507–12.
36) Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52 Suppl

1:546-52. 37) Domoney C. **Treatment of vaginal atrophy**. Womens Health (Lond Engl) 2014;10:191–200.

38) Pickar JH. **Emerging therapies for postmenopausal vaginal atrophy**. Maturitas 2013;75:3–6.

39) Talwar GP, Dar SA, Rai MK, Reddy KV, Mitra D, Kulkarni SV, et al. A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int J Antimicrob Agents 2008;32:180-5.
40) Telefo PB, Moundipa PF, Tchana AN, Tchouanguep Dzickotze C, Mbiapo FT. Effects of an aqueous extract of Aloe buettneri, Justicia insularis, Hibiscus macranthus, Dicliptera verticillata on some physiological and biochemical parameters of reproduction in immature female rats. J Ethnopharmacol 1998;63:193-200.
41) Giraldi A, Rellini AH, Pfaus J, Laan E. Female sexual arousal disorders. J Sex Med 2013;10:58-73.